|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.4000 AUD | -13.04% |
|
-16.67% | -38.46% |
| 06-26 | Recce Pharmaceuticals to Raise AU$4 million via Share Placement; Shares Down 17% | MT |
| 06-24 | Recce Pharmaceuticals Requests Trading Halt Ahead of Equity Raise | MT |
| Market Cap | 116M 79.78M 70.07M 64.4M 60.39M 113M 7.52B 777M 301M 3.72B 300M 293M 12.91B | P/E 2026 * |
-5.63x | P/E 2027 * | -3.69x |
|---|---|---|---|---|---|
| Enterprise Value | 124M 85.4M 75.01M 68.93M 64.65M 121M 8.05B 831M 322M 3.98B 321M 314M 13.82B | EV / Sales 2026 * |
16.1x | EV / Sales 2027 * | 16.8x |
| Free-Float |
57.05% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -13.04% | ||
| 1 week | -16.67% | ||
| Current month | -27.27% | ||
| 1 month | -23.81% | ||
| 3 months | -13.04% | ||
| 6 months | -34.43% | ||
| Current year | -38.46% |
| 1 week | 0.37 |  | 0.5 |
| 1 month | 0.37 | | 0.58 |
| Current year | 0.37 | | 0.73 |
| 1 year | 0.28 | | 0.73 |
| 3 years | 0.28 | | 0.78 |
| 5 years | 0.28 | | 1.38 |
| 10 years | 0.13 | | 1.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
James Graham
CEO | Chief Executive Officer | - | 27/08/2020 |
Justin Reynolds
DFI | Director of Finance/CFO | - | - |
Michele Dilizia
CTO | Chief Tech/Sci/R&D Officer | - | 29/09/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
Michele Dilizia
BRD | Director/Board Member | - | 30/09/2012 |
James Graham
BRD | Director/Board Member | - | 30/04/2012 |
| Director/Board Member | - | 31/08/2022 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 02-23 | Expiration | Chief Executive Officer | 2,250,000 | 0.7781% | ||
| 13/10/25 | Expiration | Chief Executive Officer | 745,962 | 0.3217% | ||
| 20/11/24 | Buy | Chief Executive Officer | 3,000,000 | 1.2938% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -13.04% | -16.67% | +33.33% | -29.20% | 79.87M | |
| +7.13% | +9.97% | +55.80% | +160.09% | 1,077B | |
| +3.99% | +11.50% | +67.09% | +55.96% | 613B | |
| +4.20% | +17.03% | +38.97% | +91.06% | 448B | |
| +0.99% | +4.85% | +28.17% | +23.89% | 332B | |
| +1.82% | +8.19% | +41.15% | +26.80% | 293B | |
| +0.22% | +6.75% | +31.30% | +42.34% | 286B | |
| +0.73% | +8.53% | -27.33% | -39.55% | 215B | |
| +1.56% | +6.14% | +29.30% | +60.97% | 193B | |
| +3.26% | +3.33% | +15.55% | +68.24% | 159B | |
| Average | +1.09% | +5.36% | +31.33% | +46.06% | 361.62B | |
| Weighted average by Cap. | +3.85% | +8.79% | +41.84% | +80.07% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.68M 5.29M 4.65M 4.27M 4.01M 7.51M 499M 51.54M 19.95M 247M 19.88M 19.44M 856M | 8.86M 6.11M 5.37M 4.93M 4.63M 8.67M 576M 59.5M 23.03M 285M 22.95M 22.45M 989M |
| Net income | -20.45M -14.1M -12.39M -11.38M -10.68M -20M -1.33B -137M -53.15M -657M -52.96M -51.79M -2.28B | -30.9M -21.31M -18.72M -17.2M -16.13M -30.23M -2.01B -207M -80.32M -993M -80.03M -78.28M -3.45B |
| Net Debt | 8.15M 5.62M 4.94M 4.54M 4.26M 7.97M 530M 54.72M 21.18M 262M 21.11M 20.65M 909M | 33.53M 23.13M 20.31M 18.67M 17.51M 32.8M 2.18B 225M 87.15M 1.08B 86.84M 84.94M 3.74B |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/06/26 | A$0.4000 | -13.04% | 1,099,583 |
| 23/06/26 | A$0.4600 | -5.15% | 126,650 |
| 22/06/26 | A$0.4850 | +1.04% | 161,048 |
| 19/06/26 | A$0.4800 | 0.00% | 65,703 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- RCE Stock
Select your edition
All financial news and data tailored to specific country editions
